Marlborough, Mass.-based ReWalk Robotics has received clearance from Food and Drug Administration for the company’s ReStore soft exo-suit system designed for U.S. rehabilitation centers. ReStore is the only soft exo-suit with FDA clearance, and is intended for use in the treatment of stroke survivors with mobility challenges. The cost for ReStore will hover around the $100,000 mark, putting it out of reach for most patients but not rehab facilities. The technology should improve and lower costs. The global stroke management market is forecast to reach $37 billion by 2023, according to Allied Market Research.
On June 8, International Monetary Fund Managing Director Christine Lagarde warned that the growing presence of tech players leveraging big data and artificial intelligence technology could significantly disrupt the world’s financial system.